J&J subsidiary Janssen
Pharmaceuticals has agreed to
pay US$2.2 billion in fines to
resolve allegations of misbranding
and filing false claims for its
schizophrenia drug Risperdal as
well as Invega and Natrecor.
After repeated warnings from
the FDA re misleading marketing
messages targeting physicians, a
whistle blower complaint led to
further investigation.
J&J has also agreed to increased
accountability and transparency.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Nov 13
THOUGH women make up 60% of pharmacy graduates and pharmacists, they hold only 34% of leadership and ownership roles, according to Andria Aird, a community pharmacist, pharmacy owner, and Board Director of Blooms The Chemist.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.